• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medications are not effective. Personalized treatment may be the solution.

Cue is an intervention platform for digital devices that converts passively collected sensor data from smartphones into customized micro-interventions that improve mental health. We analyzed the best-fitting personalized ML models for each individual using Shapley values to discover their characteristic predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only half of people suffering from the disorder receive treatment1. To improve outcomes, healthcare professionals must be able identify and treat patients who are most likely to respond to specific treatments.

The treatment of depression can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will gain the most from specific treatments. They are using sensors on mobile phones, a voice assistant with artificial intelligence, and other digital tools. Two grants totaling more than $10 million will be used to identify the biological and behavioral factors that predict response.

To date, the majority of research on predictors for depression treatment effectiveness has centered on clinical and sociodemographic characteristics. These include demographic factors like age, sex and education, clinical characteristics including symptoms severity and comorbidities and biological markers such as neuroimaging and genetic variation.

Very few studies have used longitudinal data to predict mood of individuals. Few studies also take into consideration the fact that moods can be very different between individuals. Therefore, it is essential to develop methods that allow for the identification of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behaviour and emotions that are unique to each individual.

The team also developed a machine-learning algorithm that can identify dynamic predictors of the mood of each person's depression. The algorithm blends these individual differences into a unique "digital phenotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However the correlation was tinny (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is among the most prevalent causes of disability1, but it is often untreated and not diagnosed. In addition the absence of effective treatments and stigmatization associated with depressive disorders stop many individuals from seeking help.

To facilitate personalized treatment, identifying factors that predict the severity of symptoms is crucial. Current prediction methods rely heavily on clinical interviews, which are not reliable and only identify a handful of features associated with depression.

Machine learning can improve the accuracy of diagnosis and treatment for depression by combining continuous digital behavior patterns gathered from sensors on smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements as well as capture a variety of distinctive behaviors and activity patterns that are difficult to record using interviews.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care according to the severity of their depression. Participants with a CAT-DI score of 35 or 65 were given online support with the help of a coach. Those with a score 75 patients were referred to psychotherapy in-person.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial features. These included age, sex, education, work, and financial status; if they were divorced, married, or single; current suicidal thoughts, intentions or attempts; and the frequency with which they drank alcohol. The CAT-DI was used to rate the severity of depression symptoms on a scale of 100 to. The CAT-DI test was carried out every two weeks for those who received online support, and weekly for those who received in-person support.

Predictors of Treatment Reaction

Personalized depression treatments near me treatment is currently a top research topic, and many studies aim to identify predictors that allow clinicians to identify the most effective medications for each patient. Pharmacogenetics, for instance, is a method of identifying genetic variations that affect the way that our bodies process drugs. This enables doctors to choose the medications that are most likely to be most effective for each patient, while minimizing the time and effort involved in trials and errors, while avoid any adverse effects that could otherwise slow the progress of the patient.

Another promising approach is building models for prediction using multiple data sources, combining clinical information and neural imaging data. These models can be used to determine the most appropriate combination of variables predictors of a specific outcome, such as whether or not a drug is likely to improve the mood and symptoms. These models can be used to determine the response of a patient to treatment, allowing doctors to maximize the effectiveness of their treatment.

A new era of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables to improve predictive accuracy. These models have proven to be useful in forecasting treatment outcomes, such as the response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the norm for future clinical practice.

Research into depression's underlying mechanisms continues, as well as predictive models based on ML. Recent research suggests that depression is related to dysfunctions in specific neural networks. This suggests that individualized depression treatment will be based on targeted therapies that target these neural circuits to restore normal function.

Internet-delivered interventions can be a way to achieve this. They can provide an individualized and tailored experience for patients. A study showed that an internet-based program improved symptoms and improved quality of life for MDD patients. In addition, a controlled randomized study of a customized treatment for depression demonstrated sustained improvement and reduced side effects in a significant number of participants.

Predictors of adverse effects

In the treatment of depression, the biggest challenge is predicting and determining the antidepressant that will cause minimal or zero negative side negative effects. Many patients experience a trial-and-error method, involving a variety of medications being prescribed before settling on one that is safe and effective. Pharmacogenetics what is depression treatment an exciting new method for an efficient and specific approach to choosing antidepressant medications.

Many predictors can be used to determine which antidepressant is best to prescribe, such as gene variants, phenotypes of patients (e.g., sex or ethnicity) and the presence of comorbidities. To identify the most reliable and reliable predictors for a specific treatment, random controlled trials with larger samples will be required. This is because the identifying of interactions or moderators could be more difficult in trials that only consider a single episode of treatment per person instead of multiple sessions of ect treatment for depression and anxiety over a period of time.

Furthermore, the prediction of a patient's response to a specific medication is likely to require information on symptoms and comorbidities and the patient's prior subjective experiences with the effectiveness and tolerability of the medication. At present, only a few easily measurable sociodemographic and clinical variables are believed to be reliable in predicting the severity of MDD, such as gender, age race/ethnicity BMI and the presence of alexithymia and the severity of depressive symptoms.

Many issues remain to be resolved in the application of pharmacogenetics to treat depression. First, it is important to be able to comprehend and understand the definition of the genetic mechanisms that cause depression, and an understanding of an accurate indicator of the response to treatment. In addition, ethical concerns like privacy and the responsible use of personal genetic information, should be considered with care. In the long run the use of pharmacogenetics could provide an opportunity to reduce the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. Like any other psychiatric treatment, it is important to carefully consider and implement the plan. For now, the best course of action is to offer patients various effective depression medications and encourage them to speak with their physicians about their experiences and concerns.